Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, i... by Hecht, JR, Trarbach, T, Hainsworth, J, Major, P, Jäger, E, Wolff, R, Lloyd-Salvant, K, Bodoky, G, Pendergrass, K, Berg, W, Chen, B, Jalava, T, Meinhardt, G, Laurent, D, Lebwohl, D, Kerr, D